Clicky

Legend Biotech Corporation(LEGN) News

Date Title
Oct 16 Is Legend Biotech Corporation (LEGN) the Most Promising Biotech Stock According to Hedge Funds?
Sep 14 Legend Biotech Corporation (LEGN): Among Hedge Funds’ Top Biotech Stock Picks
Sep 12 Here’s Why TimesSquare Capital Management U.S. Focus Growth Strategy Removed Legend Biotech Corporation (LEGN) from its Portfolio
Jul 29 Is Legend Biotech Corporation (LEGN) a Good Growth Stock to Buy?
Jul 26 Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
Jun 24 Does Legend Biotech (LEGN) Have a Long Runway for Growth?
May 14 Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
May 14 Q1 2024 Legend Biotech Corp Earnings Call
May 13 Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 9 Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
Apr 22 CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Apr 11 Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Apr 8 FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Apr 8 Why Legend Biotech (LEGN) Stock Might be a Great Pick
Apr 6 Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Apr 3 Should You Continue to Hold Legend Biotech Corporation (LEGN)?
Mar 29 Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4
Mar 19 Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Mar 17 30 Biggest Biotechnology Companies in the World
Mar 15 CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma